{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "FlublokPI"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "relevance_explanation": "This quote directly references the comparison of Flublok Quadrivalent to a 'Comparator' in Study 6, supporting that Flublok Quadrivalent was evaluated against another quadrivalent vaccine in a pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100].",
      "relevance_explanation": "This quote clarifies that the 'Comparator' used in the pivotal trial was specifically Fluarix quadrivalent, confirming the head-to-head evaluation of Flublok Quadrivalent against Fluarix Quadrivalent.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}